Conferences - Results from #80

ASCO 2023: Long-Term Outcomes of Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial June 4, 2023

ASCO 2023: Primary Analysis of STARTAR: A Phase 2 Salvage Trial of ADT and Apalutamide with Radiation Therapy Followed by Docetaxel in Men with PSA Recurrent Prostate Cancer After Radical Prostatectomy June 4, 2023

ASCO 2023: ARAMON: A Phase 2, Randomized, Open-Label Study Comparing the Effects of Darolutamide Versus Enzalutamide Monotherapy on Serum Testosterone Levels in Patients with Hormone-Naive Prostate Cancer June 4, 2023

ASCO 2023: Tumor Factors and the Variation in Non-Muscle Invasive Bladder Cancer Recurrence After Transurethral Resection Surgery Between Sites: Results from the RESECT Study June 4, 2023

ASCO 2023: Discussant: Looking for Prostate Cancer: Will Novel Imaging Light the Way? June 4, 2023

ASCO 2023: Pre-Surgical 68Ga-PSMA-11 PET for Biochemical Recurrence Risk Assessment: A Surrogate of Pelvic Lymph Node Dissection? Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial June 4, 2023

ASCO 2023: PANTHER: A Prospective Trial of Apalutamide and Abiraterone Acetate plus Prednisone in Black and White Men with mCRPC June 4, 2023

ASCO 2023: Do Bone Scans Over-Stage Disease Compared to PSMA PET? an International Multicenter Retrospective Study with Blinded Independent Readers June 4, 2023

ASCO 2023: Patient Reported Quality of Life and Survival Outcomes: Analysis of ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED) in Prostate Cancer June 4, 2023

ASCO 2023: A Study of Prospective Monitoring of Patients with Recurrent Prostate Cancer Using Serial 18F-DCFPyL PSMA Imaging June 4, 2023

ASCO 2023: Enfortumab Vedotin with or Without Pembrolizumab in Patients Who Are Cisplatin-Ineligible with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer: Additional 3-Month Follow-up on Cohort K Data June 4, 2023

ASCO 2023: Health-Related Quality of Life and Pain Outcomes for Patients with mCRPC Who Received Abiraterone and Olaparib Vs Abi and Placebo in the Phase III PROpel Trial June 4, 2023

ASCO 2023: Patient-Reported Outcomes Among Men Receiving Talazoparib + Enzalutamide vs Placebo + ENZA as First-Line Treatment for mCRPC: Results from a Phase 3 Study (TALAPRO-2) June 4, 2023

ASCO 2023: Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography Disease Extent and Overall Survival in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer: An International Multicenter Retrospective Study June 3, 2023

ASCO 2023: PSMA PET Guided Salvage Radiotherapy Among Patients with Prostate Cancer in the Post-Prostatectomy Setting: A Single Center Post-Hoc Analysis June 3, 2023

ASCO 2023: The Role of Volume of Disease for Treatment Selection in Patients with mCSPC: A Living Meta-Analysis June 3, 2023

ASCO 2023: APPROACH Trial: Multimodal Approach in Patients with mHSPC: A Pragmatic, Randomized, Phase 3 Trial of Androgen-Deprivation Therapy plus Apalutamide Versus ADT plus Apalutamide and Local Treatment—Meet-URO 29 Study June 3, 2023

ASCO 2023: Building a Predictive Model for Outcomes with 177Lu-PSMA-617 in Patients with mCRPC Using VISION Data: Preliminary Results June 3, 2023

ASCO 2023: ADT and Risk of Dementia in Patients with Prostate Cancer: Clinical Outcomes from Real-World Data June 3, 2023

ASCO 2023: Tumor Dosimetry of 177Lu-PSMA-617 for the Treatment of mCRPC: Results from the VISION Trial Sub-Study June 3, 2023

Page 5 of 522